SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries

Pediatric Blood and Cancer

Volumn 60, Issue 5, 2013, Pages 719-727

  Chantada, Guillermo ^a,b   Luna Fineman, Sandra ^c   Sitorus, Rita S ^d   Kruger, Mariana ^e   Israels, Trijn ^f   Leal Leal, Carlos ^g   Bakhshi, Sameer ^h   Qaddoumi, Ibrahim ^b   Abramson, David H ⁱ   Doz, François ^j   Epelman, Sidnei ^k   Hungerford, John ^k   Desjardins, Laurence ^k   Stannard, Clare ^k   Galindo, Carlos Rodriguez ^k  

^a Hospital de Pediatria SAMIC Prof Dr Juan P Garrahan   (Argentina)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^e STELLENBOSCH UNIVERSITY   (South Africa)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^g INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^h ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j INSTITUT CURIE   (France)

^k NONE

more..

Author keywords

Developing countries; Retinoblastoma; Treatment

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; IFOSFAMIDE; TOPOTECAN; VINCRISTINE;

ADD ON THERAPY; ADJUVANT CHEMORADIOTHERAPY; ADJUVANT THERAPY; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DEVELOPING COUNTRY; ENUCLEATION; EVISCERATION; EXTERNAL BEAM RADIOTHERAPY; HEALTH CARE AVAILABILITY; HEALTH PROGRAM; HUMAN; METASTASIS; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARENTAL ATTITUDE; PARTIAL BODY RADIATION; PATIENT COMPLIANCE; PEDIATRIC SURGERY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RETINOBLASTOMA; UNSPECIFIED SIDE EFFECT;

COMBINED MODALITY THERAPY; DEVELOPING COUNTRIES; HEALTH SERVICES ACCESSIBILITY; HUMANS; NEOPLASM STAGING; RETINAL NEOPLASMS; RETINOBLASTOMA; RISK ASSESSMENT; TREATMENT OUTCOME; TREATMENT REFUSAL;

EID: 84874954241     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24468     Document Type: Article

References (72)

1. Canturk S, Qaddoumi I, Khetan V, et al. Survival of retinoblastoma in less-developed countries impact of socioeconomic and health-related indicators. Br J Ophthalmol 2010; 94: 1432-1436.
2. Kivela T. The epidemiological challenge of the most frequent eye cancer: Retinoblastoma, an issue of birth and death. Br J Ophthalmol 2009; 93: 1129-1131.
3. Sultan I, Wilson MW, Nawaiseh I, et al. Enucleation for retinoblastoma: The experience of a single center in Jordan. Int Ophthalmol 2010; 30: 407-414.
4. Sitorus RS, Moll AC, Suhardjono S, et al. The effect of therapy refusal against medical advice in retinoblastoma patients in a setting where treatment delays are common. Ophthalmic Genet 2009; 30: 31-36.
5. Gupta R, Vemuganti GK, Reddy VA, et al. Histopathologic risk factors in retinoblastoma in India. Arch Pathol Lab Med 2009; 133: 1210-1214.
6. Leal-Leal CA, Rivera-Luna R, Flores-Rojo M, et al. Survival in extra-orbital metastatic retinoblastoma: Treatment results. Clin Transl Oncol 2006; 8: 39-44.
7. Shields CL, Shields JA. Retinoblastoma management: Advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy. Curr Opin Ophthalmol 2010; 21: 203-212.
8. Wilson MW, Haik BG, Rodriguez-Galindo C. Socioeconomic impact of modern multidisciplinary management of retinoblastoma. Pediatrics 2006; 118: e331-e336.
9. Shields CL, Ramasubramanian A, Thangappan A, et al. Chemoreduction for group E retinoblastoma: Comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes. Ophthalmology 2009; 116: 544-551, e541.
10. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000; 18: 12-17.
11. National Cancer Institute PDQ® Levels of Evidence for Adult and Pediatric Cancer Treatment Studies. Last update 08/26/2010, accessed 11/02/2012. In Edition Bethesda: National Cancer Institute 2012.
12. Hunger SP, Sung L, Howard SC. Treatment strategies and regimens of graduated intensity for childhood acute lymphoblastic leukemia in low-income countries: A proposal. Pediatr Blood Cancer 2009; 52: 559-565.
13. Gallie B. Canadian guidelines for retinoblastoma care. Can J Ophthalmol 2009; 44: 639-642.
14. Rodriguez-Galindo C, Wilson MW, Chantada G, et al. Retinoblastoma: One world, one vision. Pediatrics 2008; 122: e763-e770.
15. Schvartzman E, Chantada G, Fandino A, et al. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol 1996; 14: 1532-1536.
16. Mustafa MM, Jamshed A, Khafaga Y, et al. Adjuvant chemotherapy with vincristine, doxorubicin, and cyclophosphamide in the treatment of postenucleation high risk retinoblastoma. J Pediatr Hematol Oncol 1999; 21: 364-369.
17. Bowman RJ, Mafwiri M, Luthert P, et al. Outcome of retinoblastoma in east Africa. Pediatr Blood Cancer 2008; 50: 160-162.
18. Chintagumpala M LB Eagle R, Albert D, et al. A large prospective trial of children with unilateral retinoblastoma with and without histopathologic high-risk features and the role of adjuvant chemotherapy: A Children's Oncology Group (COG) study. In ASCO. Annual Meeting, Edition 2012.
19. Sengupta S, Krishnakumar S, Sharma T, et al. Histopathology of retinoblastoma: Does standardization make a difference in reporting? Pediatr Blood Cancer 2013; 60: 336-337.
20. Leander C, Fu LC, Pena A, et al. Impact of an education program on late diagnosis of retinoblastoma in Honduras. Pediatr Blood Cancer 2007; 49: 817-819.
21. Chantada GL, Dunkel IJ, Qaddoumi I, et al. Familial retinoblastoma in developing countries. Pediatr Blood Cancer 2009; 53: 338-342.
22. Chantada G, Doz F, Antoneli CB, et al. A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 2006; 47: 801-805.
23. Linn Murphree A. Intraocular retinoblastoma: The case for a new group classification. Ophthalmol Clin North Am 2005; 18: 41-53, viii.
24. Zacharoulis S, Abramson DH, Dunkel IJ. More aggressive bone marrow screening in retinoblastoma patients is not indicated: The memorial Sloan-Kettering cancer center experience. Pediatr Blood Cancer 2006; 46: 56-61.
25. Bakhshi S, Meel R, Kashyap S, et al. Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: Correlation with IRSS staging. J Pediatr Hematol Oncol 2011; 33: e182-e185.
26. Palma J, Sasso DF, Dufort G, et al. Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant 2012; 47: 522-527.
27. Ali MJ, Reddy VA, Honavar SG, et al. Orbital retinoblastoma: Where do we go from here? J Cancer Res Ther 2011; 7: 11-14.
28. Namouni F, Doz F, Tanguy ML, et al. High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: A SFOP and SFGM study. Eur J Cancer 1997; 33: 2368-2375.
29. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer 2000; 89: 2117-2121.
30. Cozza R, De Ioris MA, Ilari I, et al. Metastatic retinoblastoma: Single institution experience over two decades. Br J Ophthalmol 2009; 93: 1163-1166.
31. Dunkel IJ, Chan HS, Jubran R, et al. High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer 2010; 55: 149-152.
32. Chan HS, Canton MD, Gallie BL. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res 1989; 9: 469-474.
33. Blaney SM, Heideman R, Berg S, et al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J Clin Oncol 2003; 21: 143-147.
34. Doz F, Khelfaoui F, Mosseri V, et al. The role of chemotherapy in orbital involvement of retinoblastoma. The experience of a single institution with 33 patients. Cancer 1994; 74: 722-732.
35. Carrim ZI, Kajaige J, Bowman RJ, et al. First-year experience of chemotherapy for advanced retinoblastoma in Tanzania: Disease profile, outcomes, and challenges in 2008. J Pediatr Ophthalmol Strabismus 2012; 49: 176-183.
36. Radhakrishnan V, Kashyap S, Pushker N, et al. Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System Stage III) treated with neoadjuvant chemotherapy: A prospective study. Ophthalmology 2012; 119: 1470-1477.
37. Abramson DH, Frank CM, Susman M, et al. Presenting signs of retinoblastoma. J Pediatr 1998; 132: 505-508.
38. Eagle RC, Jr. High-risk features and tumor differentiation in retinoblastoma: A retrospective histopathologic study. Arch Pathol Lab Med 2009; 133: 1203-1209.
39. Bhurgri Y, Muzaffar S, Ahmed R, et al. Retinoblastoma in Karachi, Pakistan. Asian Pac J Cancer Prev 2004; 5: 159-163.
40. Bellaton E, Bertozzi AI, Behar C, et al. Neoadjuvant chemotherapy for extensive unilateral retinoblastoma. Br J Ophthalmol 2003; 87: 327-329.
41. Luna-Fineman S, Alejos A, Amador G, et al. Pre-enucleation chemotherapy in advanced intraocular retinoblastoma. Central American experience: AHOPCA II. Pediatr Blood Cancer 2012; 59: 984.
42. Kashyap S, Meel R, Pushker N, et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr Blood Cancer 2012; 58: 356-361.
43. Armenian SH, Panigrahy A, Murphree AL, et al. Management of retinoblastoma with proximal optic nerve enhancement on MRI at diagnosis. Pediatr Blood Cancer 2008; 51: 479-484.
44. Zhao J, Dimaras H, Massey C, et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol 2011; 29: 845-851.
45. Chantada G, Leal-Leal C, Brisse H, et al. Is it pre-enucleation chemotherapy or delayed enucleation of severely involved eyes with intraocular retinoblastoma that risks extraocular dissemination and death? J Clin Oncol 2011; 29: 3333-3334; author reply 3335-3336.
46. Bai S, Ren R, Li B, et al. Delay in the diagnosis of retinoblastoma in China. Acta Ophthalmol 2011; 89: e72-e74.
47. Doz F, Neuenschwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: A study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1995; 13: 902-909.
48. Sastre X, Chantada GL, Doz F, et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med 2009; 133: 1199-1202.
49. Chantada GL, Dunkel IJ, de Davila MT, et al. Retinoblastoma patients with high risk ocular pathological features: Who needs adjuvant therapy? Br J Ophthalmol 2004; 88: 1069-1073.
50. Chantada GL, Casco F, Fandino AC, et al. Outcome of patients with retinoblastoma and postlaminar optic nerve invasion. Ophthalmology 2007; 114: 2083-2089.
51. Cuenca A, Giron F, Castro D, et al. Microscopic scleral invasion in retinoblastoma: Clinicopathological features and outcome. Arch Ophthalmol 2009; 127: 1006-1010.
52. Bosaleh A, Sampor C, Solernou V, et al. Outcome of children with retinoblastoma and isolated choroidal invasion. Arch Ophthalmol 2012; 130: 724-729.
53. Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, et al. The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol 2007; 29: 700-704.
54. Kingston JE, Hungerford JL, Madreperla SA, et al. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996; 114: 1339-1343.
55. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: Factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002; 133: 657-664.
56. Menon BS, Juraida E, Alagaratnam J, et al. Chemoreduction for intraocular retinoblastoma in Malaysia. J Pediatr Hematol Oncol 2007; 29: 2-4.
57. Bakhshi S, Gupta S, Gogia V, et al. Compliance in retinoblastoma. Indian J Pediatr 2010; 77: 535-540.
58. Qaddoumi I, Nawaiseh I, Mehyar M, et al. Team management, twinning, and telemedicine in retinoblastoma: A 3-tier approach implemented in the first eye salvage program in Jordan. Pediatr Blood Cancer 2008; 51: 241-244.
59. Shields CL, Shelil A, Cater J, et al. Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 2003; 121: 1571-1576.
60. Chantada GL, Fandino AC, Raslawski EC, et al. Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatr Blood Cancer 2005; 44: 455-460.
61. Antoneli CB, Ribeiro KC, Steinhorst F, et al. Treatment of retinoblastoma patients with chemoreduction plus local therapy: Experience of the AC Camargo Hospital, Brazil. J Pediatr Hematol Oncol 2006; 28: 342-345.
62. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer 1986; 53: 661-671.
63. Marees T, van Leeuwen FE, de Boer MR, et al. Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer 2009; 45: 3245-3253.
64. Chodick G, Kleinerman RA, Stovall M, et al. Risk of cataract extraction among adult retinoblastoma survivors. Arch Ophthalmol 2009; 127: 1500-1504.
65. Gobin YP, Dunkel IJ, Marr BP, et al. Intra-arterial chemotherapy for the management of retinoblastoma: Four-year experience. Arch Ophthalmol 2011; 129: 732-737.
66. Schaiquevich P, Ceciliano A, Millan N, et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer 2012; DOI: 10.1002/pbc.24356. [Epub ahead of print].
67. Trinavarat A, Chiewvit P, Buaboonnam J, et al. Selective ophthalmic arterial infusion of chemotherapeutic drugs for recurrent retinoblastoma. J Pediatr Hematol Oncol 2012; 34: e218-e221.
68. Mostert S, Arora RS, Arreola M, et al. Abandonment of treatment for childhood cancer: Position statement of a SIOP PODC Working Group. Lancet Oncol 2011; 12: 719-720.
69. Kazadi Lukusa A, Aloni MN, Kadima-Tshimanga B, et al. Retinoblastoma in the democratic republic of congo: 20-Year review from a tertiary hospital in kinshasa. J Cancer Epidemiol 2012; 2012: 920468.
70. Luna-Fineman S, Barnoya M, Bonilla M, et al. Retinoblastoma in Central America: Report from the Central American Association of Pediatric Hematology Oncology (AHOPCA). Pediatr Blood Cancer 2012; 58: 545-550.
71. Wilimas JA, Wilson MW, Haik BG, et al. Development of retinoblastoma programs in Central America. Pediatr Blood Cancer 2009; 53: 42-46.
72. Chantada GL, Fandino AC, Guitter MR, et al. Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer 2010; 55: 60-66.